Compound synthesis of small molecule Marizomib
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95019Q00016 and the solicitation is issued as a Request for Quotation (RFQ) on a Full and Open competitive basis. This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5- Simplified Procedures for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is NOT expected to exceed the simplified acquisition teshold (SAT) of $250,000.00. A Fixed-Price type of Purchase Order contract is contemplated for any resulting contract entered into as a result of this solicitation. (iii) The solicitation document and incorporated provisions and clauses are those in effect tough Federal Acquisition Circular FAC Number/Effective Date: FAC_2005-101 / 10-26-2018 (iv) The North American Industry Classification System (NAICS) code for this procurement is 325998 - All Other Miscellaneous Chemical Product and Preparation Manufacturing with associated small business size standard of 500 employees. (v) Background The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is a translational science center whose mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The Division of Pre-Clinical Innovation (DPI) at NCATS plans, conducts and uses both internal and contract resources to advance collaborative research projects across the pre-clinical phases of the translational science spectrum. NCATS is currently interested in the small molecule marizomib for a variety of neurological and oncogenic studies. Towards that goal, NCATS has a requirement to obtain contractor services to synthesize and provide 0.2 grams of this small molecule marizomib. Purpose and Objective: The purpose of this requirement is to obtain 0.2 grams of the small molecule Marizomib via a custom synthesis and a report detailing the synthesis, including purity information. Product Description: The Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to achieve the Salient Characteristics of this requirement specified in the following: 1. Contractor will synthesize 0.2 grams of Marizomib, in accordance with: a. SMILES code: C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl, b. CAS: 437742-34-2, c. Purity will be 95% or above, d. Enantiopurity will be 95% or above. 2. Contractor will provide a comprehensive report detailing: a. Synthesis steps and procedures, b. NMR, LC-MS, and Chiral LC traces, especially of the final product. 3. Contractor will provide the desired compound within 20 weeks of the award date; 4. Contractor will be available via e-mail for discussions, as necessary; 5. Contractor will send weekly updates, via e-mail, regarding progress towards the synthesis, including synthetic schemes, and one final report detailing the synthesis, including purity information. Contractors shall possess the technical capability to achieve the salient government essential features of this requirement and document evidence of being able to provide the subject requirement that will allow for the essential features described herein to be achieved. Period of Performance/Delivery: Vendor shall deliver compounds and stated results within approximately 20 weeks after a receipt of order (ARO). GOVERNMENT RESPONSIBILITIES The Government will review and approve the data, reports, and products generated. DELIVERY OR DELIVERABLES 1. 0.2 grams of Marizomib, pursuant to the purity qualifications above 2. 1 report detailing the synthesis, and including purity information. REPORTING REQUIREMENTS 1. Contractor will be expected to stay in e-mail contact with the government representative, with reports issued at least monthly. Data Rights/Confidentiality of Information: Data may be produced as part of this contract. The government retains rights to this data. All data is the property of NCATS unless otherwise specified. Contractor will keep data generated strictly confidential. Any information the contractor is to release must be authorized by the government before release. Contractor will not write, nor publish articles, except with the express written permission of the government. Inspection and Acceptance Offerors should indicate an estimated delivery time in full after receipt of an order. Inspection and acceptance will be performed at NCATS, located at 9800 Medical Center Drive, Rockville, MD 20850. (vi) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. The following is provided as an addendum to FAR clause 52.212-1, Instructions to Offerors: Offerors should indicate an estimated delivery time in full after receipt of material to be tested. (vii) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. The following is an addendum to 52.212-2: Responses received to this RFQ will be evaluated on a trade-off basis. The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. Price is an unscored component. Technical Evaluation criteria when combined are significantly more important when compared to price. Each quotation will be evaluated in strict conformity with the evaluation factors, utilizing written critiques. The evaluation will be based upon the demonstrated capabilities of the prospective contractor in relation to the needs of the project as set forth in the RFQ and will use an adjectival evaluation rating scheme based on the following responses: Excellent (Risk level: Very low); Good (Risk level: Low); Acceptable (Risk Level: Neutral); Marginal (Risk level: High); Unacceptable (Risk level: Very high). (1) Technical Experience: Offerors shall clearly indicate possessing the capability to achieve the essential salient characteristic features of this requirement. The Offeror must indicate in its quotation the ability to provide all of the requirements and the ability to meet the delivery requirements. Offerors will be evaluated based on the following sub-factors: -Understanding of the work, including creativity and thoroughness shown in understanding the objectives of the SOW and planned execution of the project. -Documenting the technical experience as an independent company performing contract chemical synthesis, including specific past performance on prior similar efforts specified within this SOW; -Possessing capability for preparative SFC chiral comatography on site; -Performing contract chemical syntheses and multi-step custom chemical syntheses of known compounds, ideally syntheses which exceed 10 linear steps; -Appropriate mix and balance of education and training of team members, including published journal articles or manuscripts in the same or related scientific field; Offeror's submitting a response must provide a completed Price Quote to be evaluated and considered for award. Price quotes must include FIXED-PRICES per unit and total fixed cost, including shipping cost and estimated time of delivery after receipt of order, and warranty and training considerations. Responses will be evaluated based on contractor's ability to meet the government's required SALIENT CHARACTERISTICS stated in this notice and on ability to deliver required supplies. Responses to this solicitation must include clear and convincing evidence of the Offeror's capability of fulfilling the requirement as it relates to the essential government requirements stated in this solicitation. (viii) The provision at FAR Clause 52.212-3, Offeror Representations and Certifications Commercial Items, applies to this acquisition. (ix) The provision at FAR Clause 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition. No addendum to FAR Clause 52.212-4, Contract Terms and Conditions-Commercial Items, Offeror Representations and Certifications Commercial Items, applies to this acquisition. No additional addenda are applicable. (x) The provision of FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition and is incorporated by reference. The following clauses listed in FAR clause 52.212-5 are applicable to the acquisition: 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2016) 52.222-3 Convict Labor (June 2003) 52.222-19 Child Labor-Cooperation With Authorities and Remedies (Jan 2018) 52.222-21 Prohibition of Segregated Facilities (Apr 2015) 52.222-26 Equal Opportunity (Sep 2016) 52.222-36 Equal Opportunity for Workers With Disabilities (Jul 2014) 52.222-50 Combating Trafficking in Persons (Mar 2015) 52.223-18 Encouraging Contractor Policies to Ban Text Messaging While Driving (Aug 2011) 52.225-1 Buy American - Supplies (May 2014) 52.225-13 Restriction on Certain Foreign Purchases (Jun 2008) 52.232-33 Payment by Electronic Funds Transfer-- System for Award Management (Jul. 2013) In addition, the following FAR provisions are applicable to this solicitation and incorporated by reference: 52.204-7 System for Award Management (Oct 2018), 52.204-13 System for Award Management Maintenance (Oct 2018), 52.204-16 Commercial and Government Entity Code Reporting (Jul 2016), 52.204-18 Commercial and Government Entity Code Maintenance (Jul 2016). (xi) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiii) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The PRICE QUOTE shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria and a price proposal. Offerors must include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications Commercial Items, with their offer, or provide a copy of the valid certifications registrations and Representation and Certifications from the System of Award Management (SAM) applications at www.SAM.gov, which may be indicated on the Offeror's cover sheet. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All Offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received no later than the date specified in this announcement. Late responses will not be accepted. All responses must reference the solicitation number identified in this announcement. Responses must be submitted electronically to hunter.tjugum@nih.gov. Facsimile responses will not be accepted. For information regarding this solicitation, contact Mr. Hunter Tjugum by email at hunter.tjugum@nih.gov or by phone at 301-827-5304.. 75N95019Q00016 Department of Health and Human Services National Institutes of Health
11/21/18, 10:13 AM